Industries / Health / Pharmaceuticals
Contract drug manufacturing
Contract drug manufacturing is the industry of companies, called CDMOs (contract development and manufacturing organizations), that work out how to make a drug company's medicine and then make it, in their own plants, under contract.
1933
Robert Pauli Scherer, a chemical engineer in Detroit, founded the Gelatin Products Company to make soft gelatin capsules on a rotary die machine he had invented, and it soon took work from a growing list of drug makers; the analyst Jim Miller names R.P. Scherer among the few dedicated contract makers of finished medicines before 1996.
36
Milestones achieved across 6 domains.
10
To watch for: announced, not yet confirmed outside.
12
Open deliverables. Nobody has shipped them.
In one minute
Where it started
Before 1996, by Jim Miller's account in Pharmaceutical Technology, large drug companies made products for one another on an informal basis, fine-chemical firms made the building blocks, and a few specialists filled narrow niches: R.P. Scherer made soft capsules, Ben Venue Laboratories freeze-dried injectable drugs and Vetter filled syringes. There was no contract sector for medicines grown in cells, so Amgen and Genentech built their own plants. From 1996 Custom Pharmaceuticals became Patheon and bought plants that drug companies were shedding, Lonza bought Celltech's contract biologics business, and Cardinal Health bought R.P. Scherer, the first piece of what became Catalent.
Where it stands
Contract makers now run plants as large as those of the companies they serve. Lonza, which now does only contract work, reported 2025 sales of CHF 6.5 billion, and in 2024 it bought a whole Genentech plant from Roche. Samsung Biologics, founded in 2011, says its plants hold 784,000 litres of cell-culture tanks. Drug companies also buy plants back: Novo Holdings bought Catalent in December 2024 and passed three of its filling plants to Novo Nordisk. Governments treat the industry as a question of supply. India pays makers to produce ingredients at home, the US BIOSECURE Act of December 2025 limits federal money for "biotechnology companies of concern", and the FDA now inspects more foreign plants without warning.
What is open
Most of what a contract maker knows sits in private files: the process it was handed, the quality agreement it signed, its schedule and its run data. The open jobs below build public versions from records that are already published, such as regulators' product files, warning letters, company filings and worked case studies, and use them to test current AI models and low-cost robots. None of them needs a drug, a plant or a licence.
Domains
AchievedWatch forOpen
Domain
Progress
Last achieved
Watch for
Open
Process development
Turning a drug company's laboratory recipe into a process that a plant can run the same way every time, at the scale and cost the medicine needs.
7 · 1 · 2
Last achievedQuality by Design, counted2021
Watch for20,000 reactions to train models
2
openActive ingredients
Making the active pharmaceutical ingredient (API), the substance in a medicine that has the effect, by chemistry, for drug companies that do not make it themselves.
7 · 3 · 2
Last achievedA US law on suppliers2025
Watch forThe first barred-supplier list
2
openBiologics
Contract makers grow protein medicines, such as antibodies, in tanks of living cells for drug companies that have no plant of their own or need more room than they have.
5 · 2 · 2
Last achievedMany bags instead of tanks2025
Watch forCopying a plant exactly
2
openFill and finish
Fill-and-finish plants put a finished medicine into sterile vials, syringes or cartridges, freeze-dry it where needed, then seal, inspect and pack it, and many drug companies hire contract makers to do it.
6 · 1 · 2
Last achievedA drug company buys fillers2024
Watch forFreeze-drying in hours
2
openQuality and inspections
This is how drug companies and regulators check a contract maker: the written split of duties, the drug company's own audits, and inspections by regulators.
6 · 1 · 2
Last achievedRemote reviews kept after COVID2025
Watch forSurprise inspections abroad
2
openMoving a process between plants
This is technology transfer: handing a working process, with its documents and know-how, from a drug company or one plant to another, and getting regulators to accept the change.
5 · 2 · 2
Last achievedA hub for mRNA know-how2021
Watch forDigital handovers
2
open
Advances to build with
1 research note
Open in contract drug manufacturing
3 of 12 open deliverables
Open · Process development
Route planners against plant routes
A test set of approved, non-controlled small-molecule medicines for which both the first published route and the route used for commercial manufacture are public, for example in Organic Process Research & Development papers. Route-planning software proposes a route for each target, and each plan is scored on number of steps, whether its starting materials can be bought, estimated PMI and how close it comes to the commercial route.
Built with what exists
AiZynthFinder (AstraZeneca, MIT licence) and ASKCOS, both open source; commercial planners such as Elsevier's Reaxys synthesis planning, which Lonza uses in its route-scouting service; the RetroCast scoring approach; the ACS GCI PMI calculators. An open-weight model such as Mistral Large 4 can be added as a further entrant; the note "A trillion open parameters" covers its release and licence.
Open · Active ingredients
Ingredient makers by medicine
For each of the 370 WHO essential medicines on the US market that the FDA examined in 2019, a public list of the companies holding an active US drug master file (DMF, the file an API maker lodges with the FDA so its clients can refer to it) or a European certificate of suitability (CEP) for its API, with each holder's country, refreshed every quarter. It shows who can supply, not who does.
Built with what exists
the FDA's quarterly DMF list (third quarter 2026, a 51.5 MB spreadsheet); the European Directorate for the Quality of Medicines' certificates catalogue (holder name, CEP type and number); a language model to match holder names to countries, with a person checking each match.
Open · Biologics
Who makes each antibody
A public table of every antibody medicine authorised in the European Union. Each row names a plant listed as a maker of the medicine's active substance, says whether that plant belongs to the drug's owner or to a contract maker, and quotes the source line.
Built with what exists
The EMA's product-information PDFs; pdftotext; Python; a language model such as Claude to pull plant names and addresses, with a person checking each one. The note "Seven more flagged" covers Claude reviewing drug-making records.
Where it sits
Broader
